# Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

> **NCT04480125** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT04480125
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-20
- **Primary completion:** 2022-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480125, "Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT04480125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*